Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave to Trade as Part of Nasdaq Biotech Index

NEW YORK, Nov. 15 (GenomeWeb News) - Third Wave has been added the Nasdaq Biotechnology Index as part of the exchange's semi-annual listing update, the exchange said last week.

 

According to the exchange, all securities being added to the Index will be phased into Nasdaq's Opening Cross on Nov. 16.

 

A total of 11 companies were added to the index and two were removed during the Nasdaq's update.

 

Securities currently in the Index must meet the maintenance criteria of $100 million in market capitalization and 50,000 shares average daily trading volume, according to the Nasdaq.

 

With Third Wave, 143 companies trade as part of the Biotech Index. Among them are the genomics companies Accelrys, Affymetrix, Caliper Life Sciences, Ciphergen Biosystems, DeCode Genetics, Gene Logic, Harvard Bioscience, Illumina, Invitrogen, Orchid Biosciences, and Qiagen.

 

"Index securities not meeting the maintenance criteria are retained in the Index provided that such security met the maintenance criteria in the previous semi-annual ranking," the exchange said on its web site. "Securities not meeting the maintenance criteria for two consecutive rankings are removed."

 

Changes occur after the close of trading on the third Friday in May and November using March and September closing price and volume data and April and October publicly available total share outstanding data, the Nasdaq said.

 

Click here for more information about the Nasdaq biotech index.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.